<DOC>
	<DOCNO>NCT00356486</DOCNO>
	<brief_summary>The purpose study compare early virological response ( EVR = undetectable [ ribonucleic acid-hepatitis C virus ] RNA-HCV reduction &gt; 2 log10 ) patient chronic hepatitis C coinfected HIV treat induction dos peginterferon alpha-2a ( 40 KD ) 270 µg/week ribavirin 1600 mg/day 4 week , follow 8 week treatment peginterferon alpha-2a ( 40 KD ) 180 µg/week ribavirin 1000-1200 mg/day versus treatment peginterferon alpha-2a ( 40 KD ) 180 µg/week ribavirin 1000-1200 mg/day 12 week .</brief_summary>
	<brief_title>Viral Kinetics Treatment With Peginterferon Alpha-2a , Ribavirin Epoetin β Patients Coinfected HCV/HIV</brief_title>
	<detailed_description>This study seek ascertain whether treatment high dos PEGASYS ( 270 µg/week ) ribavirin ( 1600 mg/day ) first four week achieve plasma concentration product blood need reduce half-life virion accelerate elimination thereof . This would bring viral kinetic curve coinfected patient closer model describe mono-infected HCV patient , probably achieve improve rate response week 12 ( early virological response ) posterior week 72 ( sustain virological response ) . Therefore , patient randomise treatment two different dos , 270 µg 180 µg PEGASYS , 1600 mg 1000-1200 mg ribavirin .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Serological evidence chronic hepatitis C infection antiHCV antibody test Detectable RNAHCV plasma level genotype 1 4 ALT serum activity upper limit normality Chronic liver disease consistent chronic hepatitis C infection biopsy obtain two year prior inclusion study Serological evidence HIV1 infection , diagnose EnzymeLinked Immunosorbent Assay ( ELISA ) confirm Westernblot . Patients CD4 cell count &gt; 200 /µl Stable status HIV1 infection , investigator 's opinion , word , patient expect progress study . Patients treat stable antiretroviral therapy ( HAART ) , include nucleoside analogue , least 6 week baseline assessment Patients receive HAART therapy Negative pregnancy test urine blood Women currently pregnant lactation period . Patients whose companion pregnant . Therapy interferon ( IFN ) ribavirin previous time . Patients cirrhosis hepatic biopsy . Documented suspicion ultrasound hepatocarcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Co-infection</keyword>
	<keyword>Induction dose</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV Infections</keyword>
</DOC>